This is my third Soleno Therapeutics (NASDAQ: SLNO ) article , following 06/2025's "Soleno Therapeutics: Overbought On VYKAT Approval Enthusiasm". In Overbought, I rated Soleno as a "Hold". It has since dropped ~24%. I am taking another look to seeWriting under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of inve ...